Goldman Sachs
CHRS icon

Goldman Sachs’s Coherus Oncology CHRS Stock Holding History

Goldman Sachs’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-29,900
Closed -$485K – 5228
2020
Q1 		$485K Buy
+29,900
New +$552K ﹤0.01% 4229

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Goldman Sachs's CHRS Position: Q1 2026 in Review

Goldman Sachs increased its Coherus Oncology (CHRS) stake by 127% in Q1 2026, buying an estimated $691K and bringing the position to 696,158 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4978.

Goldman Sachs first reported a position in CHRS in Q1 2015 and has held it in 43 quarters since. The position peaked at $26.9M in Q3 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Goldman Sachs held 696,158 shares of Coherus Oncology worth $1.18M as of Q1 2026.
  • Goldman Sachs bought 389,021 Coherus Oncology shares in Q1 2026, an estimated $691K.
  • Coherus Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4978 holding.
  • Goldman Sachs first reported a position in Coherus Oncology in Q1 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Coherus Oncology position peaked at $26.9M in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.